

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Khalid KADER
Christian H. COYLE

Serial No.: 10/598,726

Filed: September 8, 2006

For: METHODS AND COMPOSITIONS FOR
SCREENING INVOLVING
ENDOTHELIAL CELLS UNDER
SHEARING CONDITIONS

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: IOWA:061US

Confirmation No.: 9434

CERTIFICATE OF ELECTRONIC TRANSMISSION	
I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:	
May 18, 2007	_____
Date	Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:061US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 18, 2007

Form PTO-1449 (modified)		Atty. Docket No. IOWA:061US	Serial No. 10/598,726
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Khalid KADER Christian H. COYLE	
		Filing Date: September 8, 2006	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	6,335,010	01/01/02	Chien <i>et al.</i>	424	93.2	06/30/97

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	De Keulenaer <i>et al.</i> , "Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase," <i>Circ. Res.</i> , 82:1094-1101, 1998.
	C2	Griendling <i>et al.</i> , "NAD(P)H oxidase: role in cardiovascular biology and disease," <i>Circ. Res.</i> , 86:494-501, 2000.
	C3	Hwang <i>et al.</i> , "Oscillatory shear stress stimulates endothelial production of O ₂ from p47 ^{phox} -dependent NAD(P)H oxidases, leading to monocyte adhesion," <i>J. Bio. Chem.</i> , 278:47291-47298, 2003.
	C4	Kader <i>et al.</i> , "Cationic lipid-mediated transfection of bovine aortic endothelial cells inhibits their attachment," <i>J. Biomed. Materials Res.</i> , 60:405-410, 2002.
	C5	Kader <i>et al.</i> , "eNOS-Overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation <i>in vitro</i> ," <i>Tissue Engineering</i> , 6:241-251, 2000.
	C6	Masatsugu <i>et al.</i> , "Shear stress attenuates endothelin and endothelin-converting enzyme expression through oxidative stress," <i>Regul. Pept.</i> , 111:13-19, 2003.
	C7	Muller-Glauser <i>et al.</i> , "Development of small-diameter vascular prostheses covered with human endothelial cells: possibilities and limits of <i>in vitro</i> -tests," <i>Artex</i> , 5:34-50, 1988.
	C8	Nerem, "Vascular fluid mechanics, the arterial wall, and atherosclerosis," <i>J. Biomech. Engineering</i> , 114:274-282, 1992.

25733158.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. IOWA:061US	Serial No. 10/598,726
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Khalid KADER Christian H. COYLE	
		Filing Date: September 8, 2006	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Tarpey <i>et al.</i> , "Chemiluminescent detection of oxidants in vascular tissue: lucigenin but not coelenterazine enhances superoxide formation," <i>Circ. Res.</i> , 84:1203-1211, 1999.

25733158.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.